Lupus, also known as the disease of 1,000 faces due to its complex features comes with different signs and symptoms that involve the joints, skin, kidneys, blood cells, brain, heart and lungs.
It is a lifelong systemic autoimmune disease that occurs when the body’s immune system becomes hyperactive and attacks its own normal healthy tissues and organs which causes a lot of inflammation that affect many different body systems.
The disease affects as many as 1 in 1,000 people, and is caused by the immune system mistakenly attacking healthy cells. But its wide variety of symptoms and manifestations can make it difficult to tell who is sick, or what they’re actually suffering from.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.
